Literature DB >> 24172327

Advances in prostate cancer treatment.

Dominic Trewartha1, Kimberley Carter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24172327     DOI： 10.1038/nrd4068

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

2.  Castration-resistant prostate cancer: mechanisms, targets, and treatment.

Authors:  Teresa Maria Santos Amaral; Daniela Macedo; Isabel Fernandes; Luis Costa
Journal:  Prostate Cancer       Date:  2012-03-05
  2 in total
  25 in total

1.  Synthesis and activity of tumor-homing peptide iRGD and histone deacetylase inhibitor valproic acid conjugate.

Authors:  Zheng-Hong Peng; Jindřich Kopeček
Journal:  Bioorg Med Chem Lett       Date:  2014-03-12       Impact factor: 2.823

2.  Drug repositioning for prostate cancer: using a data-driven approach to gain new insights.

Authors:  QuanQiu Wang; Rong Xu
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

3.  PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.

Authors:  Kanak Raina; Jing Lu; Yimin Qian; Martha Altieri; Deborah Gordon; Ann Marie K Rossi; Jing Wang; Xin Chen; Hanqing Dong; Kam Siu; James D Winkler; Andrew P Crew; Craig M Crews; Kevin G Coleman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

Review 4.  Prostate MR Imaging for Posttreatment Evaluation and Recurrence.

Authors:  Sonia Gaur; Baris Turkbey
Journal:  Radiol Clin North Am       Date:  2017-11-27       Impact factor: 2.303

5.  Novel Gastrin-Releasing Peptide Receptor Targeted Near-Infrared Fluorescence Dye for Image-Guided Surgery of Prostate Cancer.

Authors:  Amerigo Pagoto; Francesca Garello; Giada Maria Marini; Martina Tripepi; Francesca Arena; Paola Bardini; Rachele Stefania; Stefania Lanzardo; Giovanni Valbusa; Francesco Porpiglia; Matteo Manfredi; Silvio Aime; Enzo Terreno
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

6.  HMGB1-mediated autophagy confers resistance to gemcitabine in hormone-independent prostate cancer cells.

Authors:  Yi-Xiang Zhang; Ye-Qing Yuan; Xue-Qi Zhang; Dong-Long Huang; Yu-Ying Wei; Jiang-Gen Yang
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

7.  Silibinin derivatives as anti-prostate cancer agents: Synthesis and cell-based evaluations.

Authors:  Bao Vue; Sheng Zhang; Xiaojie Zhang; Konstantinos Parisis; Qiang Zhang; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Eur J Med Chem       Date:  2015-12-24       Impact factor: 6.514

8.  Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling.

Authors:  Jill Gallaher; Leah M Cook; Shilpa Gupta; Arturo Araujo; Jasreman Dhillon; Jong Y Park; Jacob G Scott; Julio Pow-Sang; David Basanta; Conor C Lynch
Journal:  Clin Exp Metastasis       Date:  2014-08-31       Impact factor: 5.150

9.  Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms.

Authors:  Wei Wang; Jiang-Jiang Qin; Xin Li; Guanyu Tao; Qiang Wang; Xuming Wu; Jianwei Zhou; Xiaolin Zi; Ruiwen Zhang
Journal:  Carcinogenesis       Date:  2018-07-30       Impact factor: 4.944

Review 10.  Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.

Authors:  Francesca V Mertan; Matthew D Greer; Sam Borofsky; Ismail M Kabakus; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Top Magn Reson Imaging       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.